Hims & Hers plans to enter peptides market before end of 2026, awaiting FDA rulemaking
Hims & Hers CEO Andrew Dudum said the company is waiting on full and final FDA rulemaking before bringing peptides to market, with plans to enter the peptides market before the end of 2026. The company also signed a deal worth up to $30 million for peptide API manufacturing know-how in July 2026.
Detected & updated continuously · Source: Nebula
Story subjects
Sources
@himshouse
🚨 $HIMS CEO ANDREW DUDUM ON PEPTIDES TIMELINE: "WE ARE WAITING ON FULL AND FINAL RULEMAKING FROM THE FDA BEFORE BRINGING PEPTIDES TO MARKET"
@business
Hims & Hers plans to jump into the peptides market before the end of the year, with executives seeing opportunity to seize on a booming corner of the health industry https://t.co/8bm8zZXi7i
@himshouse
🚨 BREAKING: $HIMS SIGNED A DEAL WORTH UP TO $30 MILLION FOR PEPTIDE API MANUFACTURING KNOW-HOW Not an acquisition of a company -- this is a tech/expertise transfer so Hims can make certain peptide APIs in-house From the 10-Q: "In July 2026, the Company entered into a one-time